Top Page
RemeGen Co. Ltd. Class H
(9995)
RemeGen Co. Ltd. Class H (9995) vs. iShares MSCI Hong Kong ETF (EWH)
RemeGen Co. Ltd. Class H Business Overview & Revenue Model
RemeGen Co. Ltd. Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.72B | 1.08B | 767.77M | 1.42B | 0.00 |
| Gross Profit | 1.37B | 822.99M | 497.84M | 1.36B | 0.00 |
| EBITDA | -1.19B | -1.25B | -805.70M | 402.05M | -661.56M |
| Net Income | -1.47B | -1.51B | -997.84M | 276.26M | -727.09M |
Balance Sheet | |||||
| Total Assets | 5.50B | 5.53B | 6.02B | 4.16B | 4.12B |
| Cash, Cash Equivalents and Short-Term Investments | 759.53M | 743.39M | 2.07B | 1.76B | 2.77B |
| Total Debt | 2.67B | 1.26B | 165.03M | 102.78M | 197.69M |
| Total Liabilities | 3.51B | 2.09B | 1.04B | 712.79M | 523.07M |
| Stockholders Equity | 1.99B | 3.44B | 4.98B | 3.45B | 3.59B |
Cash Flow | |||||
| Free Cash Flow | -1.38B | -2.35B | -2.02B | -353.71M | -1.14B |
| Operating Cash Flow | -1.11B | -1.50B | -1.26B | 263.63M | -660.08M |
| Investing Cash Flow | -248.24M | -817.65M | -841.56M | -637.95M | -479.06M |
| Financing Cash Flow | 1.39B | 978.31M | 2.43B | -626.90M | 3.90B |
RemeGen Co. Ltd. Class H Technical Analysis
RemeGen Co. Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.81B | -0.22 | -40.01% | 2.29% | 21.48% | -2.11% | |
47 Neutral | HK$51.64B | ― | -45.12% | ― | 47.62% | 28.72% | |
| ― | $5.22B | 0.93 | -6.09% | ― | ― | ― | |
| ― | €3.25B | ― | -29.51% | ― | ― | ― | |
54 Neutral | HK$46.13B | ― | -16.25% | ― | 44.21% | 46.11% | |
| ― | HK$35.73B | 37.41 | 12.36% | 1.30% | ― | ― | |
70 Outperform | HK$45.60B | 48.33 | 27.37% | ― | 2.57% | 18.79% |
RemeGen Co. Ltd. Class H Corporate Events
RemeGen Co., Ltd. announced that its drug Telitacicept met the primary endpoint in a Phase III clinical trial for primary Sjögren’s syndrome in China. This marks a significant milestone as Telitacicept is the first BLyS/APRIL dual-target fusion protein drug to complete such a study in this field. The trial demonstrated the drug’s efficacy and safety, addressing a significant unmet clinical need in Sjögren’s syndrome treatment. The company plans to submit a Biologics License Application to the National Medical Products Administration of China and present the data at international conferences. Telitacicept has also been recommended by multiple guidelines in China and has received fast track designation from the U.S. FDA for its Sjögren’s syndrome indication.
RemeGen Co., Ltd. announced the purchase of a principal-guaranteed wealth management product worth RMB350.0 million from CMB Yantai Branch, using idle self-owned funds. This transaction, approved by the Board, is considered a discloseable transaction under Hong Kong’s Listing Rules, reflecting the company’s strategic cash management approach to optimize returns on its idle funds.
RemeGen Co., Ltd. has announced a board meeting scheduled for August 22, 2025, to review and approve the interim financial results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market position and stakeholder interests.
RemeGen Co., Ltd. held its 2025 second class meeting of H shareholders, where key resolutions were passed, including changes to the company’s registered capital and amendments to its Articles of Association. The meeting saw participation from shareholders representing approximately 19.67% of the total issued H shares, with all resolutions receiving the required majority vote, indicating strong shareholder support for the proposed changes.
RemeGen Co., Ltd. has announced a 2025 second class meeting of H shareholders to be held on July 31, 2025. The meeting will address special resolutions including changes to the company’s registered capital, the cancellation of its supervisory committee, and amendments to its Articles of Association and Rules of Procedures for shareholder meetings. These changes may significantly impact the company’s governance structure and operational procedures, potentially affecting its market positioning and stakeholder interests.
RemeGen Co., Ltd. announced the results of its 2024 Annual General Meeting and the 2025 first class meetings for A and H shareholders. All proposed resolutions were passed, including the approval of the 2024 financial accounts, annual profit distribution plan, and re-appointment of accounting firms. Special resolutions such as the issuance of additional shares and amendments to the Articles of Association were also approved, indicating strong shareholder support for the company’s strategic initiatives.
RemeGen Co., Ltd. has entered into a license agreement with Vor Biopharma Inc., granting Vor Bio exclusive rights to develop and commercialize Telitacicept outside Greater China. This strategic partnership, which includes a $125 million consideration and potential milestone payments up to $4,105 million, aims to accelerate the global expansion of Telitacicept, enhancing RemeGen’s brand value and cash flow while diversifying R&D risks. The agreement is expected to provide innovative treatment options worldwide and strengthen RemeGen’s position in the biotechnology industry.
RemeGen Co., Ltd. has successfully completed the placement of 19,000,000 new H Shares, which represents approximately 9.11% of the total issued H Shares and 3.37% of the total issued Shares. This completion, which took place on May 29, 2025, resulted in an increase of the total issued Shares from 544,608,243 to 563,608,243, and the total issued H Shares from 189,581,239 to 208,581,239. The placement was conducted at a price of HK$42.44 per share to at least six independent placees, marking a significant step in the company’s capital expansion efforts.
RemeGen Co., Ltd. announced that its drug Telitacicept has received marketing approval from the National Medical Products Administration in China for treating generalized myasthenia gravis. The approval follows successful phase III clinical trials demonstrating significant efficacy and safety, with Telitacicept outperforming placebo in improving patient symptoms. This approval is expected to address the unmet medical needs of myasthenia gravis patients in China and supports RemeGen’s ongoing efforts to validate the drug’s effectiveness globally.
RemeGen Co., Ltd. has announced its 2024 Annual General Meeting (AGM) scheduled for June 26, 2025, where shareholders will consider and approve various resolutions. The agenda includes approving the 2024 financial accounts, profit distribution plan, and re-appointment of accounting firms, as well as special resolutions like issuing additional shares and amending company regulations. These decisions are pivotal for the company’s strategic direction and governance structure, potentially impacting its market positioning and stakeholder interests.
RemeGen Co., Ltd. has announced the convening of its 2025 first class meeting of H shareholders to consider significant resolutions, including the change of registered capital, the cancellation of the supervisory committee, and amendments to the company’s Articles of Association and Rules of Procedures. These proposed changes are expected to streamline the company’s governance structure and potentially enhance operational efficiency, reflecting a strategic move to strengthen its market position and stakeholder engagement.
RemeGen Co., Ltd. has established a Remuneration and Appraisal Committee to enhance its corporate governance and remuneration management system. This committee is responsible for evaluating and recommending remuneration strategies and policies for directors and senior management, as well as overseeing performance appraisals and incentive schemes. The committee’s recommendations, once approved by the Board, will be presented for consideration at the shareholders’ meeting. This move is expected to strengthen the company’s governance and align its management’s incentives with corporate goals, potentially impacting its market positioning positively.
RemeGen Co., Ltd. has announced proposed amendments to its Articles of Association to enhance corporate governance and compliance. Key changes include the cancellation of the Supervisory Committee, with its functions being transferred to the Audit Committee, and adjustments to shareholder rights and meeting procedures. These amendments aim to align with regulatory standards and are subject to shareholder approval, reflecting the company’s commitment to maintaining robust governance structures.
RemeGen Co., Ltd. announced changes to its Nomination Committee, effective May 26, 2025, with Mr. Wang Weidong stepping down and Dr. Su Xiaodi joining as a member. These changes align with the amended Corporate Governance Code and aim to enhance the company’s governance practices, improving board effectiveness and diversity.
RemeGen Co., Ltd. has announced the composition of its board of directors and their roles within the company. The board includes executive, non-executive, and independent non-executive directors, with specific members assigned to various committees such as audit, remuneration and appraisal, nomination, and strategy. This announcement provides clarity on the governance structure of the company, which could impact its strategic direction and decision-making processes.
RemeGen Co., Ltd. has established an Audit Committee under its Board to enhance internal control, audit, and related transaction systems, ensuring effective management in financial reporting, risk management, and corporate governance. This committee is responsible for reviewing the company’s financial information, supervising internal and external audits, and monitoring compliance with relevant laws and regulations, thereby strengthening the company’s governance structure.
RemeGen Co., Ltd. has established a Nomination Committee under its Board to enhance corporate governance by regulating the selection and appointment of directors. The committee is tasked with ensuring that board members possess the necessary skills, experience, and diversity to align with the company’s strategic objectives and values, while also making recommendations on appointments and succession planning for senior management.
RemeGen Co., Ltd. announced the placement of new H shares under a general mandate, with the aim of raising approximately HK$806.36 million in gross proceeds. The net proceeds, estimated at HK$796 million, will be used to further invest in the research and development of Telitacicept and for general corporate purposes. This strategic move represents around 10.02% of the existing H shares and 3.49% of the total issued shares, potentially enhancing the company’s market position and supporting its growth initiatives. The placement will be conducted by placing agents to a minimum of six independent investors, subject to certain conditions and termination rights.